Business Trends– category –
-
H.B. Fuller Unveils EternaBond® Dry Technology System for RV Manufacturing: Dramatically Improving Watertightness and Production Speed
H.B. Fuller Blog USA Overview H.B. Fuller has launched its EternaBond® Dry Technology System (DTS) for RV manufacturing, which significantly enhances watertightness and production speed. This tape-form product replaces multi-step sealing... -
ElevationSpace Secures ¥6.4 Billion in Series B Funding, Reaching ¥10.1 Billion Total to Advance Earth Return Services from Space
Fundrive Japan Overview ElevationSpace, a Tohoku University spin-off, successfully closed a Series B funding round, raising ¥6.4 billion ($43 million) and bringing its total capital raised to ¥10.1 billion ($68 million). The Japanese sta... -
Unimicron Initiates Mass Production at New Thai ABF Substrate Plant to Meet Surging AI Server Demand, Diversifying Geopolitical Risk
DigiTimes Japan Taiwan Overview Unimicron has commenced mass production at its new facility in Thailand, addressing the escalating demand for Ajinomoto Build-up Film (ABF) substrates, especially for AI servers. This strategic expansion a... -
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib) as First Broad RAS-Targeted Medicine for Metastatic Pancreatic Cancer
MarketScreener USA Overview Revolution Medicines announced that its RASONQUE™ (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer, has received U.S. FDA approval. RASONQUE had previously been granted Br... -
U.S. FDA Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine, Aligned with 2026 Fall Vaccination Guidance
Pfizer USA Overview Pfizer and BioNTech have received U.S. FDA approval for their XFG-adapted COVID-19 vaccine. This approval aligns with the FDA's guidance on the recommended composition for COVID-19 vaccines to be used in the United St... -
Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership
PR Newswire South Korea Overview Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This stra... -
AusperBio Secures $120M Series C Funding to Advance Phase 3 for Chronic Hepatitis B ASO Therapy AHB-137 and Accelerate Au-HALO™ Platform’s HBV siRNA Development
BioSpace Global Overview AusperBio Therapeutics has successfully completed a $120 million Series C financing round to vigorously advance its lead antisense oligonucleotide (ASO) therapy, AHB-137, through Phase 3 enrollment and towards co... -
EMA’s CHMP Endorses Marketing Authorization Expansion for Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) for Childhood Obesity in Rare Genetic Disorders (Ages 2+)
Bio-Research.AI Europe Overview Rhythm Pharmaceuticals announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization expansion for IMCIVREE (setmelanoti... -
Molecular Glue Degraders Expand Druggable Proteome in Cancer Research: Simple Structure Boosts CNS Delivery Potential
Facebook USA Overview Molecular glue degraders, small molecules that stabilize interactions between otherwise non-interacting proteins, are expanding the 'druggable' proteome in cancer research through targeted protein degradation. Unlik... -
NJ Cancer Care Offers New Hope for Refractory Cancer Patients with Bispecific Antibody Therapy
NJ Cancer Care USA Overview NJ Cancer Care highlights bispecific antibody therapy as a groundbreaking treatment utilizing the patient's immune system to target and destroy cancer cells, offering new hope for those unresponsive to standar...
